Drug intelligence / Profile preview

clorotepine

Development stage: Unknown
Modality: Small Molecules
Administration: Oral, Intramuscular

Overview

Clorotepine is a typical antipsychotic drug belonging to the dibenzothiazepine class. It has been used primarily in some European countries for the treatment of schizophrenia and other psychotic disorders. Clorotepine acts as an antagonist at dopamine receptor D2, serotonin receptor 2A, adrenergic, histaminergic, and muscarinic acetylcholine receptors. Its mechanism of action is similar to other typical antipsychotics, with primary effects attributed to dopamine receptor antagonism leading to reduced psychotic symptoms.

Other names: 2-chloro-11-(4-methyl-1-piperazinyl)dibenzo[b,f][1,4]thiazepine

Targets

DRD1 (Dopamine D1 Receptor)HTR2A (Serotonin receptor 5-HT2A)mAChR (Muscarinic acetylcholine receptors)DRD2 (Dopamine D2 Receptor)HRH1 (Histamine H1 Receptor)ADRA1A (α1A)

Beyond the preview

Go deeper on clorotepine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on clorotepine.

Explore the full profile